Cabozantinib plus androgen deprivation therapy in patients with androgen-dependent metastatic prostate cancer.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.6_suppl.169
Abstract: 169Background: Cabozantinib (Cabo), a tyrosine kinase inhibitor of c-Met and VEGFR2, modulates the tumor microenvironment in a therapeutically favorable manner. We combined Cabo with androgen deprivation therapy (ADT) in patients (pts) with androgen-dependent metastatic prostate… read more here.
Keywords: androgen dependent; dependent metastatic; deprivation therapy; cancer ... See more keywords